Does Mounjaro cause itching? Mounjaro (tirzepatide) is a GLP-1 and GIP receptor agonist licensed in the UK for type 2 diabetes and weight management. Whilst gastrointestinal side effects are most common, some patients report itching during treatment. According to the UK Summary of Product Characteristics, itching can occur as part of injection site reactions (affecting up to 1 in 10 people) or as a manifestation of hypersensitivity. Understanding when itching is a minor, self-limiting reaction versus a sign of a more serious allergic response is essential for safe use of this medication.

Does Mounjaro Cause Itching?

Mounjaro (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. Whilst the most commonly reported adverse effects relate to the gastrointestinal system—such as nausea, vomiting, and diarrhoea—some patients have reported experiencing itching (pruritus) during treatment.

According to the UK Summary of Product Characteristics (SmPC), itching can occur primarily in two contexts: as part of injection site reactions (reported as common, affecting up to 1 in 10 people) or as a manifestation of hypersensitivity reactions. Injection site reactions may manifest as redness, swelling, or localised itching at the site where Mounjaro is administered subcutaneously. These reactions are typically mild and self-limiting, resolving within a few days without specific intervention.

In less common instances, itching may be part of a broader hypersensitivity or allergic reaction to tirzepatide or one of its excipients. Such reactions can range from mild skin manifestations to more serious systemic responses. It is important to distinguish between localised injection site reactions and generalised pruritus, as the latter may indicate a more significant immune-mediated response. Additionally, itching can occasionally be associated with other dermatological conditions unrelated to Mounjaro, or may coincide with changes in metabolic control, weight loss, or concurrent medications. Patient reports and post-marketing surveillance continue to inform our understanding of tirzepatide's safety profile.

When to Seek Medical Advice About Itching

Patients experiencing itching whilst taking Mounjaro should assess the severity, distribution, and associated symptoms to determine whether medical advice is required. Mild, localised itching at the injection site that resolves within a few days is generally not a cause for concern and can often be managed with simple measures. However, certain features warrant prompt medical evaluation.

Call 999 or go to A&E immediately if itching is accompanied by:

• Widespread rash or hives (urticaria) covering large areas of the body

• Swelling of the face, lips, tongue, or throat (angioedema), which may indicate anaphylaxis

• Difficulty breathing, wheezing, or chest tightness

• Dizziness, rapid heartbeat, or feeling faint

• Severe or worsening skin reactions, including blistering, peeling, or painful lesions

These symptoms may represent a serious hypersensitivity reaction requiring immediate cessation of Mounjaro and emergency medical intervention. Anaphylaxis, although rare, is a recognised risk with injectable medicines and constitutes a medical emergency. Do not re-administer Mounjaro if hypersensitivity is suspected until reviewed by a clinician.

Contact your GP, diabetes specialist nurse, or NHS 111 if:

• Itching persists for more than a week despite simple measures

• The itching is severe enough to disrupt sleep or daily activities

• You develop new skin changes, such as a rash, discolouration, or lesions away from the injection site

• You are uncertain whether the itching is related to Mounjaro or another cause

Your healthcare provider can assess whether the itching represents an adverse drug reaction, an injection technique issue, or an unrelated dermatological condition. They may recommend temporarily discontinuing Mounjaro, switching injection sites, or investigating alternative causes. Never stop or alter your prescribed medication without consulting a healthcare professional, as abrupt discontinuation may affect glycaemic control or weight management goals.

Managing Itching While Taking Mounjaro

For mild, localised itching at the injection site, several practical strategies can provide relief and may prevent recurrence. Ensuring correct injection technique is paramount: Mounjaro should be administered subcutaneously into the abdomen, thigh, or upper arm, rotating injection sites with each dose to minimise tissue irritation. Avoid injecting into areas that are tender, bruised, red, or hard, and follow the storage and preparation instructions in the Patient Information Leaflet, including allowing the pen to reach room temperature before injection if recommended.

Simple measures to alleviate injection site itching include:

• Applying a cool compress or ice pack wrapped in a clean cloth to the affected area for 10–15 minutes

• Using an emollient or moisturiser to keep the skin hydrated and reduce irritation

• Avoiding scratching, which can introduce infection or worsen inflammation

• Wearing loose, breathable clothing to minimise friction over the injection site

• Taking a non-sedating over-the-counter antihistamine (such as cetirizine or loratadine) if itching is more generalised, after consulting a pharmacist or GP to check suitability and potential interactions

If itching appears to be related to a specific injection site, consider alternating between different anatomical areas (abdomen, thigh, upper arm) to allow previously used sites to recover fully. Some patients find that certain areas are more prone to reactions than others.

For persistent or generalised itching, your healthcare provider may recommend further investigation to exclude other causes, such as dermatological conditions (eczema, urticaria), hepatic or renal impairment, or interactions with other medications. Blood tests to assess liver function, kidney function, and markers of inflammation may be appropriate. If a clinician diagnoses an inflammatory skin condition, they may prescribe topical treatments. In some cases, a switch to an alternative GLP-1 receptor agonist may be considered if the itching is deemed to be a true adverse reaction to tirzepatide. Always discuss any persistent symptoms with your diabetes care team to ensure safe and effective management.

Other Common Side Effects of Mounjaro

Mounjaro's side effect profile is predominantly characterised by gastrointestinal disturbances, which are consistent with the mechanism of action of GLP-1 and GIP receptor agonists. These agents slow gastric emptying and modulate appetite signalling, leading to predictable effects on the digestive system. According to the UK SmPC, the most frequently reported adverse effects include:

Gastrointestinal side effects (very common, affecting more than 1 in 10 people):

• Nausea — often most pronounced during the initial weeks of treatment or following dose escalation

• Diarrhoea — may be mild to moderate and typically improves with continued use

• Vomiting — can occur, particularly if dietary modifications are not made

• Constipation — less common than diarrhoea but reported in some patients

• Abdominal pain or discomfort — usually transient

• Decreased appetite — a therapeutic effect contributing to weight loss but may be troublesome for some

These gastrointestinal symptoms are generally dose-dependent and tend to diminish over time as the body adapts to the medication. Following the dose-escalation schedule in the SmPC can help minimise these effects, and patients should be counselled on dietary strategies, such as eating smaller, more frequent meals and avoiding high-fat foods.

Other notable side effects include:

• Injection site reactions — redness, swelling, itching, or bruising at the injection site (common, affecting up to 1 in 10 people)

• Hypoglycaemia — particularly when Mounjaro is used in combination with insulin or sulfonylureas; contact your healthcare provider if this occurs as dose adjustment of these agents may be necessary

• Fatigue or dizziness — may occur, especially during initial treatment

• Increased heart rate — a modest increase has been observed in clinical trials

Other important adverse effects that require medical attention include:

• Acute pancreatitis — presenting as severe, persistent abdominal pain radiating to the back, often accompanied by nausea and vomiting; seek urgent medical care

• Gallbladder disease — including cholecystitis and cholelithiasis, associated with rapid weight loss; seek urgent medical assessment for severe, persistent upper abdominal pain, especially if accompanied by fever or jaundice

• Diabetic retinopathy complications — particularly in patients with pre-existing retinopathy experiencing rapid improvement in glycaemic control; discuss any new or worsening visual symptoms with an eye care professional

Patients should be advised to report any new or worsening symptoms to their healthcare provider promptly. Regular monitoring, including HbA1c, weight, and assessment for adverse effects, is recommended. You can also report suspected side effects directly to the MHRA Yellow Card Scheme at yellowcard.mhra.gov.uk or via the Yellow Card app. Understanding the full spectrum of potential side effects enables patients and clinicians to make informed decisions about continuing, adjusting, or discontinuing Mounjaro therapy.

Frequently Asked Questions